Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Neoplasms

Katherine Tarlock, Emily C Merkel, Todd Cooper, Corinne Summers, Monica Thakar, Paul A Carpenter, Aleksandra Petrovic, Ross Goshorn, Robert Irwin, Ted Gooley, Marie Bleakley, Ann Dahlberg

Blood (2023) 142 (Supplement 1): 4956.

https://doi.org/10.1182/blood-2023-181256

Published: 2023

Journal Articles

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Richard J Marrero, Vivek M. Shastri, Richard Aplenc, Todd Cooper, Todd A. Alonzo, Alan S Gamis, Jim Wang, Soheil Meshinchi, E. Anders Kolb, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2023-187515

Published: 2023

Journal Articles

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Benjamin J Huang, Lauren K. Meyer, Adam Lamble, Jim Wang, Rhonda E Ries, Alan S Gamis, Richard Aplenc, Katherine Tarlock, Todd Cooper, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Joseph Chewning, William G. Woods, John T. Horan

Blood (2023) 142 (Supplement 1): 655.

https://doi.org/10.1182/blood-2023-186955

Published: 2023

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

Establishing Real-World Data-Driven Response Criteria in Pediatric Acute Myeloid Leukemia

Richard Aplenc, Yimei Li, Julianne Ani, Caitlin W. Elgarten, Lisa D'Errico, Todd Cooper, E. Anders Kolb, Maria Monica Gramatges, Meret Henry, Tamara P. Miller, Rajen Mody, Elaine Morgan, Regina M. Myers, Jessica A. Pollard, Alix Seif, Brian T. Fisher, Kelly D. Getz

Blood (2023) 142 (Supplement 1): 726.

https://doi.org/10.1182/blood-2023-185647

Published: 2023

Journal Articles

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

Nam Nguyen, Phani Krishna Parcha, Abderrahmane Tagmount, Bailey Gregory, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Todd A. Alonzo, Richard Aplenc, Alan S Gamis, Todd Cooper, E. Anders Kolb, Soheil Meshinchi, Stanley Pounds, Christopher Vulpe, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2023-178832

Published: 2023

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Weili Sun, MDPhD, Paul S Gaynon, MD, Richard Sposto, PhD, Henrique Bittencourt, MD, Andrew E. Place, MDPhD, Yoav H Messinger, MD, Chris Fraser, MD, Luciano Dalla-Pozza, MD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Xiaojing Yang, PhD, Gangning Liang, PhD, Peter A. Jones, PhD DSc, Alan S. Wayne, MD, Todd Cooper, DO

Blood (2014) 124 (21): 3764.

https://doi.org/10.1182/blood.V124.21.3764.3764

Published: 2014

Journal Articles

Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia

Aarthi Jayanthan, Todd Cooper, DO, Sandra E. Dunn, PhD, Victor A. Lewis, MD, Aru Narendran, MD, PhD

Blood (2012) 120 (21): 3573.

https://doi.org/10.1182/blood.V120.21.3573.3573

Published: 2012

Journal Articles

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Lia Gore, MD, Margaret E. Macy, M.D., Francoise Mechinaud, MD, Aru Narendran, MD, PhD, Frank Alvaro, MD, Carola A.S. Arndt, MD, Phillip Barnette, MD, Jessica Boklan, MD, Todd Cooper, DO, Laura Martin, MD, W Tcheng, MD, Peter Tarassoff, MD, Mark M Jones, MD, Soheil Meshinchi, MD, PhD, Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 1517.

https://doi.org/10.1182/blood.V120.21.1517.1517

Published: 2012

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., John Perentesis, MD, James A. Whitlock, MD, Jeffrey W. Taub, MD, Terzah M. Horton, MD, PhD, Alan S. Gamis, MD, MPH, Bassem I. Razzouk, MD

Blood (2012) 120 (21): 3604.

https://doi.org/10.1182/blood.V120.21.3604.3604

Published: 2012

Journal Articles

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Todd Cooper, DO, Richard Sposto, PhD, Jeannette Cassar, Elena Eckroth, CCRC, Jemily Malvar, M.S., Paul Gaynon, MD, Steven Dubois, MD, Bill H Chang, MD, PhD, Lia Gore, MD, Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2012) 120 (21): 3605.

https://doi.org/10.1182/blood.V120.21.3605.3605

Published: 2012

Journal Articles

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

Y. Lucy Liu, MD, PhD, Yan Yan, MD, Shelly Y. Lensing, MS, Todd Cooper, DO, Peter D. Emanuel, MD

Blood (2012) 120 (21): 2558.

https://doi.org/10.1182/blood.V120.21.2558.2558

Published: 2012

Journal Articles

High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.

Phoenix A. Ho, MD, Todd Alonzo, PhD, Robert B. Gerbing, M.A., Jessica A. Pollard, MD, Susana C. Raimondi, Betsy A. Hirsch, PhD, Todd Cooper, DO, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2530.

https://doi.org/10.1182/blood.V120.21.2530.2530

Published: 2012

Journal Articles

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

Nobuko Hijiya, Blythe Thomson, Michael S. Isakoff, Lewis B. Silverman, Peter G. Steinherz, Michael J. Borowitz, Richard Kadota, Todd Cooper, Violet Shen, Gary Dahl, Jaideep V. Thottassery, Sima Jeha, Kelly Maloney, Jo-Anne Paul, Elly Barry, William L. Carroll, Paul S. Gaynon

Blood (2011) 118 (23): 6043–6049.

https://doi.org/10.1182/blood-2011-08-374710

Published: 2011

Journal Articles

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Todd A. Alonzo, PhD, Phoenix A. Ho, MD, Robert B. Gerbing, MA, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2010) 116 (21): 761.

https://doi.org/10.1182/blood.V116.21.761.761

Published: 2010

Journal Articles

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Nobuko Hijiya, MD, Jo-Anne Paul, Michael J. Borowitz, MD, PhD, Blythe Thomson, MD, Michael Isakoff, MD, Lewis B. Silverman, MD, Peter G Steinherz, MD, Richard Kadota, MD, Joseph G Pressey, MD, Violet Shen, MD, Roland Chu, MD, Todd Cooper, DO, Sima Jeha, MD, Bassem I. Razzouk, MD, Michael E. Rytting, MD, Elly Barry, MD, MMSc, William L. Carroll, MD, Paul Gaynon, MD

Blood (2010) 116 (21): 866.

https://doi.org/10.1182/blood.V116.21.866.866

Published: 2010

Journal Articles

Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group

Soheil Meshinchi, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Phoenix A. Ho, MD, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD

Blood (2010) 116 (21): 1702.

https://doi.org/10.1182/blood.V116.21.1702.1702

Published: 2010

Journal Articles

CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia

Tanya C. Watt, MD, MSc, Sunita Park, MD, Todd Cooper, DO

Blood (2010) 116 (21): 2124.

https://doi.org/10.1182/blood.V116.21.2124.2124

Published: 2010

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, John Perentesis, James A. Whitlock, MD, Elizabeth Raetz, MD, William L. Carroll, MD, Alan S. Gamis, MD, B. I. Razzouk

Blood (2009) 114 (22): 3076.

https://doi.org/10.1182/blood.V114.22.3076.3076

Published: 2009

NARROW

Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Neoplasms

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Europeanpediatric Acute Leukemia (EuPAL) Registry

Establishing Real-World Data-Driven Response Criteria in Pediatric Acute Myeloid Leukemia

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group

CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia

AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only